Fidelity leads $100m Series C round in China-based clinical CRO dMed
Fidelity leads $100m Series C round in China-based clinical CRO dMed Source: Volodymyr Hryshchenko/Unsplash Premium dMed Biopharmaceutical, a clinical contract research organisation (CRO) with operations in China and the US, announced on Thursday that it has raised $100 million in a Series C round of financing led by Fidelity Management & Research Company. Continue reading this story with a subscription to DealStreetAsia. Contact us for corporate subscriptions at subs@dealstreetasia.com. Sign up for our newsletter - The Daily Brief Opt out of receiving The...
Source: dealstreetasia.com